Cargando…

MZ1 co-operates with trastuzumab in HER2 positive breast cancer

BACKGROUND: Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor activity. In this work, we have evaluated the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noblejas-López, María del Mar, Nieto-Jiménez, Cristina, Galán-Moya, Eva M., Tebar-García, David, Montero, Juan Carlos, Pandiella, Atanasio, Burgos, Miguel, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980639/ https://www.ncbi.nlm.nih.gov/pubmed/33741018 http://dx.doi.org/10.1186/s13046-021-01907-9

Ejemplares similares

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
por: Nieto-Jimenez, Cristina, et al.
Publicado: (2020)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
por: Burgos, Miguel, et al.
Publicado: (2022)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Mapping Bromodomains in breast cancer and association with clinical outcome
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2021)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
por: Nieto, Celia, et al.
Publicado: (2020)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2016)

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
por: Montero, Juan Carlos, et al.
Publicado: (2009)

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation
por: Centa, Ariana, et al.
Publicado: (2018)

Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer
por: Martínez‐Canales, Sandra, et al.
Publicado: (2018)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3p9j6h9b6v7f7rks5n13r86hhn